NVAX

SEC source: 0001209191-21-002621 · doc4.xml · nonDerivative · entry 14

Trizzino John · CIK 0001468534 · EVP, CMO and CBO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 793

F1 · kind: The transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person.

F8 · kind: The reporting person received 506 shares of common stock upon the net exercise of 1,149 stock appreciation rights. The reporting person forfeited 59 shares of common stock underlying the stock appreciation rights representing the base value and 584 shares of common stock underlying the stock appreciation rights to satisfy the withholding tax obligations resulting from the exercise, using the closing stock price on January 5, 2021 of $116.24.

SEC source: 0001209191-21-002621 · doc4.xml · nonDerivative · entry 13

Trizzino John · CIK 0001468534 · EVP, CMO and CBO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 1,377

F1 · kind: The transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person.

F8 · kind: The reporting person received 506 shares of common stock upon the net exercise of 1,149 stock appreciation rights. The reporting person forfeited 59 shares of common stock underlying the stock appreciation rights representing the base value and 584 shares of common stock underlying the stock appreciation rights to satisfy the withholding tax obligations resulting from the exercise, using the closing stock price on January 5, 2021 of $116.24.

SEC source: 0001209191-21-002621 · doc4.xml · nonDerivative · entry 12

Trizzino John · CIK 0001468534 · EVP, CMO and CBO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 1,436

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person.

F8 · kind: The reporting person received 506 shares of common stock upon the net exercise of 1,149 stock appreciation rights. The reporting person forfeited 59 shares of common stock underlying the stock appreciation rights representing the base value and 584 shares of common stock underlying the stock appreciation rights to satisfy the withholding tax obligations resulting from the exercise, using the closing stock price on January 5, 2021 of $116.24.

SEC source: 0001209191-21-002621 · doc4.xml · nonDerivative · entry 11

Trizzino John · CIK 0001468534 · EVP, CMO and CBO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 287

F1 · kind: The transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person.

F7 · price: The reported price is a weighted average price. These shares were sold in multiple transactions at prices ranging from $115.06 to $115.15, inclusive. The reporting person undertakes to provide to Novavax, Inc., any security holder of Novavax, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each price within the range set forth in this footnote.

SEC source: 0001209191-21-002621 · doc4.xml · nonDerivative · entry 10

Trizzino John · CIK 0001468534 · EVP, CMO and CBO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 636

F1 · kind: The transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person.

F6 · price: The reported price is a weighted average price. These shares were sold in multiple transactions at prices ranging from $113.94 to $114.76, inclusive. The reporting person undertakes to provide to Novavax, Inc., any security holder of Novavax, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each price within the range set forth in this footnote.

SEC source: 0001209191-21-002621 · doc4.xml · nonDerivative · entry 9

Trizzino John · CIK 0001468534 · EVP, CMO and CBO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 2,136

F1 · kind: The transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person.

F5 · price: The reported price is a weighted average price. These shares were sold in multiple transactions at prices ranging from $112.74 to $113.70, inclusive. The reporting person undertakes to provide to Novavax, Inc., any security holder of Novavax, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each price within the range set forth in this footnote.

SEC source: 0001209191-21-002621 · doc4.xml · nonDerivative · entry 8

Trizzino John · CIK 0001468534 · EVP, CMO and CBO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 5,636

F1 · kind: The transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person.

F4 · price: The reported price is a weighted average price. These shares were sold in multiple transactions at prices ranging from $111.73 to $112.72, inclusive. The reporting person undertakes to provide to Novavax, Inc., any security holder of Novavax, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each price within the range set forth in this footnote.

SEC source: 0001209191-21-002621 · doc4.xml · nonDerivative · entry 7

Trizzino John · CIK 0001468534 · EVP, CMO and CBO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 9,830

F1 · kind: The transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person.

F3 · price: The reported price is a weighted average price. These shares were sold in multiple transactions at prices ranging from $110.73 to $111.70, inclusive. The reporting person undertakes to provide to Novavax, Inc., any security holder of Novavax, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each price within the range set forth in this footnote.

SEC source: 0001209191-21-002621 · doc4.xml · nonDerivative · entry 6

Trizzino John · CIK 0001468534 · EVP, CMO and CBO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 13,994

F1 · kind: The transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person.

F2 · price: The reported price is a weighted average price. These shares were sold in multiple transactions at prices ranging from $109.72 to $110.65, inclusive. The reporting person undertakes to provide to Novavax, Inc., any security holder of Novavax, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each price within the range set forth in this footnote.

SEC source: 0001209191-21-002621 · doc4.xml · nonDerivative · entry 5

Trizzino John · CIK 0001468534 · EVP, CMO and CBO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 17,694

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person.

SEC source: 0001209191-21-002621 · doc4.xml · nonDerivative · entry 4

Trizzino John · CIK 0001468534 · EVP, CMO and CBO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 11,445

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person.

SEC source: 0001209191-21-002621 · doc4.xml · nonDerivative · entry 3

Trizzino John · CIK 0001468534 · EVP, CMO and CBO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 9,363

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person.

SEC source: 0001209191-21-002621 · doc4.xml · nonDerivative · entry 2

Trizzino John · CIK 0001468534 · EVP, CMO and CBO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 7,695

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person.

SEC source: 0001209191-21-002621 · doc4.xml · nonDerivative · entry 1

Trizzino John · CIK 0001468534 · EVP, CMO and CBO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 5,481

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person.

SEC source: 0001209191-21-005735 · doc4a.xml · nonDerivative · entry 1

Trizzino John · CIK 0001468534 · EVP, Chief Commercial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 866

F1 · kind: The transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person.

F2 · kind: The reporting person received 579 shares of common stock upon the net exercise of 1,149 stock appreciation rights. The reporting person forfeited 59 shares of common stock underlying the stock appreciation rights representing the base value and 511 shares of common stock underlying the stock appreciation rights to satisfy the withholding tax obligations resulting from the exercise, using the closing stock price on January 5, 2021 of $116.24.

F3 · shares: This amendment to the original Form 4 filed on January 7, 2021 is being filed to correct the number of shares reported as forfeited by the reporting person to satisfy withholding tax obligations resulting from the exercise of 1,149 stock appreciation rights on January 5, 2021.

SEC source: 0001209191-21-001380 · doc4.xml · derivative · entry 9

YOUNG JAMES F · CIK 0001219864 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 10,000

Underlying: Common Stock · 10,000 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F3 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of the Company's common stock.

F5 · derivative.exercise_date: Fifty percent (50%) of the RSUs subject to this grant under the Company's Amended and Restated 2015 Stock Incentive Plan, as amended, vested on January 1, 2021, and the remaining fifty percent (50%) of the RSUs subject to this grant will vest on July 1, 2021, in each case subject to continued service on the Company's Board of Directors through the vesting date.

F5 · derivative.expiration_date: Fifty percent (50%) of the RSUs subject to this grant under the Company's Amended and Restated 2015 Stock Incentive Plan, as amended, vested on January 1, 2021, and the remaining fifty percent (50%) of the RSUs subject to this grant will vest on July 1, 2021, in each case subject to continued service on the Company's Board of Directors through the vesting date.

SEC source: 0001209191-21-001380 · doc4.xml · nonDerivative · entry 5

YOUNG JAMES F · CIK 0001219864 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 10,000

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F3 · price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of the Company's common stock.

SEC source: 0001209191-21-001404 · doc4.xml · derivative · entry 2

DOUGLAS RICHARD · CIK 0001021015 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 1,000 shares

Expires 2021-03-10

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001209191-21-001404 · doc4.xml · nonDerivative · entry 1

DOUGLAS RICHARD · CIK 0001021015 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 28,500

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001209191-21-001380 · doc4.xml · derivative · entry 8

YOUNG JAMES F · CIK 0001219864 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 10,000 shares

Expires 2021-04-19

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001209191-21-001380 · doc4.xml · derivative · entry 7

YOUNG JAMES F · CIK 0001219864 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 1,000 shares

Expires 2021-03-10

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001209191-21-001380 · doc4.xml · nonDerivative · entry 4

YOUNG JAMES F · CIK 0001219864 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

F2 · price: The reported price is a weighted average price. These shares were sold in multiple transactions at prices ranging from $113.47 to $113.78, inclusive. The reporting person undertakes to provide to the Company, any security holder of the Company, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each price within the range set forth in this footnote.

SEC source: 0001209191-21-001380 · doc4.xml · nonDerivative · entry 3

YOUNG JAMES F · CIK 0001219864 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 2,000

F1 · price: The reported price is a weighted average price. These shares were sold in multiple transactions at prices ranging from $112.45 to $113.43, inclusive. The reporting person undertakes to provide to Novavax, Inc. (the "Company"), any security holder of the Company, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each price within the range set forth in this footnote.

SEC source: 0001209191-21-001380 · doc4.xml · nonDerivative · entry 2

YOUNG JAMES F · CIK 0001219864 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 11,000

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001209191-21-001380 · doc4.xml · nonDerivative · entry 1

YOUNG JAMES F · CIK 0001219864 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 1,000

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001209191-20-063833 · doc4.xml · derivative · entry 2

Herrmann John A III · CIK 0001610928 · EVP, Chief Legal Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 6,300

Underlying: Common Stock · 6,300 shares

Expires not disclosed

F2 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of the Company's common stock.

F3 · derivative.exercise_date: One-third (1/3) of the RSUs subject to this grant under the Company's Plan will vest on each of the first three (3) anniversaries of the Grant Date, subject to continued employment through each such vesting date.

F3 · derivative.expiration_date: One-third (1/3) of the RSUs subject to this grant under the Company's Plan will vest on each of the first three (3) anniversaries of the Grant Date, subject to continued employment through each such vesting date.

SEC source: 0001209191-20-063833 · doc4.xml · derivative · entry 1

Herrmann John A III · CIK 0001610928 · EVP, Chief Legal Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 12,700

Underlying: Common Stock · 12,700 shares

Expires 2030-12-14

F1 · derivative.exercise_date: Twenty-five percent (25%) of the shares subject to this option grant under the Novavax, Inc. (the "Company") Amended and Restated 2015 Stock Incentive Plan, as amended (the "Plan"), will vest on the first anniversary of the December 14, 2020 grant date (the "Grant Date"), and the remaining seventy-five percent (75%) of the shares will vest in equal monthly installments over the following three (3) years, in each case subject to continued employment through such vesting date.

SEC source: 0001209191-20-063829 · doc4.xml · derivative · entry 2

Trizzino John · CIK 0001468534 · EVP, CMO and CBO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 4,800

Underlying: Common Stock · 4,800 shares

Expires not disclosed

F2 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of the Company's common stock.

F3 · derivative.exercise_date: One-third (1/3) of the RSUs subject to this grant under the Company's Plan will vest on each of the first three (3) anniversaries of the Grant Date, subject to continued employment through each such vesting date.

F3 · derivative.expiration_date: One-third (1/3) of the RSUs subject to this grant under the Company's Plan will vest on each of the first three (3) anniversaries of the Grant Date, subject to continued employment through each such vesting date.

SEC source: 0001209191-20-063829 · doc4.xml · derivative · entry 1

Trizzino John · CIK 0001468534 · EVP, CMO and CBO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 9,500

Underlying: Common Stock · 9,500 shares

Expires 2030-12-14

F1 · derivative.exercise_date: Twenty-five percent (25%) of the shares subject to this option grant under the Novavax, Inc. (the "Company") Amended and Restated 2015 Stock Incentive Plan, as amended (the "Plan"), will vest on the first anniversary of the December 14, 2020 grant date (the "Grant Date"), and the remaining seventy-five percent (75%) of the shares will vest in equal monthly installments over the following three (3) years, in each case subject to continued employment through such vesting date.

SEC source: 0001209191-20-063827 · doc4.xml · derivative · entry 2

Erck Stanley C · CIK 0001342826 · Director · President and CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 20,900

Underlying: Common Stock · 20,900 shares

Expires not disclosed

F2 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of the Company's common stock.

F3 · derivative.exercise_date: One-third (1/3) of the RSUs subject to this grant under the Company's Plan will vest on each of the first three (3) anniversaries of the Grant Date, subject to continued employment through each such vesting date.

F3 · derivative.expiration_date: One-third (1/3) of the RSUs subject to this grant under the Company's Plan will vest on each of the first three (3) anniversaries of the Grant Date, subject to continued employment through each such vesting date.

SEC source: 0001209191-20-063827 · doc4.xml · derivative · entry 1

Erck Stanley C · CIK 0001342826 · Director · President and CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 41,700

Underlying: Common Stock · 41,700 shares

Expires 2030-12-14

F1 · derivative.exercise_date: Twenty-five percent (25%) of the shares subject to this option grant under the Novavax, Inc. (the "Company") Amended and Restated 2015 Stock Incentive Plan, as amended (the "Plan"), will vest on the first anniversary of the December 14, 2020 grant date (the "Grant Date"), and the remaining seventy-five percent (75%) of the shares will vest in equal monthly installments over the following three (3) years, in each case subject to continued employment through such vesting date.

SEC source: 0001209191-20-063828 · doc4.xml · derivative · entry 2

Glenn Gregory M · CIK 0001342823 · President, R&D

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 9,300

Underlying: Common Stock · 9,300 shares

Expires not disclosed

F2 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of the Company's common stock.

F3 · derivative.exercise_date: One-third (1/3) of the RSUs subject to this grant under the Company's Plan will vest on each of the first three (3) anniversaries of the Grant Date, subject to continued employment through each such vesting date.

F3 · derivative.expiration_date: One-third (1/3) of the RSUs subject to this grant under the Company's Plan will vest on each of the first three (3) anniversaries of the Grant Date, subject to continued employment through each such vesting date.

SEC source: 0001209191-20-063828 · doc4.xml · derivative · entry 1

Glenn Gregory M · CIK 0001342823 · President, R&D

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 18,700

Underlying: Common Stock · 18,700 shares

Expires 2030-12-14

F1 · derivative.exercise_date: Twenty-five percent (25%) of the shares subject to this option grant under the Novavax, Inc. (the "Company") Amended and Restated 2015 Stock Incentive Plan, as amended (the "Plan"), will vest on the first anniversary of the December 14, 2020 grant date (the "Grant Date"), and the remaining seventy-five percent (75%) of the shares will vest in equal monthly installments over the following three (3) years, in each case subject to continued employment through such vesting date.

SEC source: 0001209191-20-062595 · doc4.xml · derivative · entry 1

MCGLYNN MARGARET G · CIK 0001215126 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 7,700

Underlying: Common Stock · 7,700 shares

Expires 2030-12-07

F1 · derivative.exercise_date: One hundred percent (100%) of the shares subject to this option grant under the Novavax, Inc. (the "Company") Amended and Restated 2015 Stock Incentive Plan, as amended, will vest one (1) year from the December 7, 2020 grant date subject to continued service on the Company's Board of Directors through the vesting date.

SEC source: 0001209191-20-062345 · doc4.xml · derivative · entry 1

YOUNG JAMES F · CIK 0001219864 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 20,000

Underlying: Common Stock · 20,000 shares

Expires not disclosed

F1 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of Novavax, Inc. (the "Company") common stock.

F2 · derivative.exercise_date: This grant was made under the Company's Amended and Restated 2015 Stock Incentive Plan, as amended, in connection with the appointment of the Reporting Person as Chair of a newly established standing Research and Development Committee of the Board of Directors of the Company. Fifty percent (50%) of the RSUs subject to this grant will vest on January 1, 2021, and the remaining fifty percent (50%) of the RSUs subject to this grant will vest on July 1, 2021, in each case subject to continued service on the Company's Board of Directors through the vesting date.

F2 · derivative.expiration_date: This grant was made under the Company's Amended and Restated 2015 Stock Incentive Plan, as amended, in connection with the appointment of the Reporting Person as Chair of a newly established standing Research and Development Committee of the Board of Directors of the Company. Fifty percent (50%) of the RSUs subject to this grant will vest on January 1, 2021, and the remaining fifty percent (50%) of the RSUs subject to this grant will vest on July 1, 2021, in each case subject to continued service on the Company's Board of Directors through the vesting date.

SEC source: 0001209191-20-059196 · doc4.xml · derivative · entry 10

Erck Stanley C · CIK 0001342826 · Director · President and CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 35,182

Underlying: Common Stock · 9,818 shares

Expires 2022-03-01

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person.

F9 · derivative.exercise_date: The shares subject to this option grant vested in four equal annual installments beginning on the first anniversary of the March 1, 2012 grant date.

SEC source: 0001209191-20-059196 · doc4.xml · derivative · entry 9

Erck Stanley C · CIK 0001342826 · Director · President and CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 42,499 shares

Expires 2021-06-22

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person.

F8 · derivative.exercise_date: The shares subject to this option grant vested in four equal annual installments beginning on the first anniversary of the June 22, 2011 grant date.

SEC source: 0001209191-20-059196 · doc4.xml · nonDerivative · entry 8

Erck Stanley C · CIK 0001342826 · Director · President and CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 20,495

F1 · kind: The transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person.

F7 · price: The reported price is a weighted average price. These shares were sold in multiple transactions at prices ranging from $93.21 to $93.78, inclusive. The reporting person undertakes to provide to the Company, any security holder of the Company, or the staff of the SEC, upon request, full information regarding the number of shares purchased at each price within the range set forth in this footnote

SEC source: 0001209191-20-059196 · doc4.xml · nonDerivative · entry 7

Erck Stanley C · CIK 0001342826 · Director · President and CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 25,404

F1 · kind: The transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person.

F6 · price: The reported price is a weighted average price. These shares were sold in multiple transactions at prices ranging from $92.21 to $93.205, inclusive. The reporting person undertakes to provide to the Company, any security holder of the Company, or the staff of the SEC, upon request, full information regarding the number of shares purchased at each price within the range set forth in this footnote

SEC source: 0001209191-20-059196 · doc4.xml · nonDerivative · entry 6

Erck Stanley C · CIK 0001342826 · Director · President and CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 42,907

F1 · kind: The transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person.

F5 · price: The reported price is a weighted average price. These shares were sold in multiple transactions at prices ranging from $89.99 to $90.90, inclusive. The reporting person undertakes to provide to the Company, any security holder of the Company, or the staff of the SEC, upon request, full information regarding the number of shares purchased at each price within the range set forth in this footnote

SEC source: 0001209191-20-059196 · doc4.xml · nonDerivative · entry 5

Erck Stanley C · CIK 0001342826 · Director · President and CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 47,505

F1 · kind: The transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person.

F4 · price: The reported price is a weighted average price. These shares were sold in multiple transactions at prices ranging from $88.97 to $89.96, inclusive. The reporting person undertakes to provide to the Company, any security holder of the Company, or the staff of the SEC, upon request, full information regarding the number of shares purchased at each price within the range set forth in this footnote

SEC source: 0001209191-20-059196 · doc4.xml · nonDerivative · entry 4

Erck Stanley C · CIK 0001342826 · Director · President and CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 58,739

F1 · kind: The transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person.

F3 · price: The reported price is a weighted average price. These shares were sold in multiple transactions at prices ranging from $87.95 to $88.89, inclusive. The reporting person undertakes to provide to the Company, any security holder of the Company, or the staff of the SEC, upon request, full information regarding the number of shares purchased at each price within the range set forth in this footnote

SEC source: 0001209191-20-059196 · doc4.xml · nonDerivative · entry 3

Erck Stanley C · CIK 0001342826 · Director · President and CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 67,045

F1 · kind: The transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person.

F2 · price: The reported price is a weighted average price. These shares were sold in multiple transactions at prices ranging from $86.95 to $87.92, inclusive. The reporting person undertakes to provide to Novavax, Inc. (the "Company"), any security holder of the Company, or the staff of the Securities and Exchange Commission (the "SEC"), upon request, full information regarding the number of shares purchased at each price within the range set forth in this footnote.

SEC source: 0001209191-20-059196 · doc4.xml · nonDerivative · entry 2

Erck Stanley C · CIK 0001342826 · Director · President and CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 72,811

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001209191-20-059196 · doc4.xml · nonDerivative · entry 1

Erck Stanley C · CIK 0001342826 · Director · President and CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 62,993

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001209191-20-059194 · doc4.xml · derivative · entry 2

COVINO GREGORY F · CIK 0001224116 · EVP, Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 8,200

Underlying: Common Stock · 8,200 shares

Expires 2030-11-16

F3 · derivative.exercise_date: Twenty-five percent (25%) of the shares subject to this option grant under the Plan will vest on the first anniversary of the Grant Date, and the remaining seventy-five percent (75%) of the shares will vest in equal monthly installments over the following three (3) years, in each case subject to continued employment through such vesting date.

SEC source: 0001209191-20-059194 · doc4.xml · derivative · entry 1

COVINO GREGORY F · CIK 0001224116 · EVP, Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 7,300

Underlying: Common Stock · 7,300 shares

Expires not disclosed

F1 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of Novavax, Inc. (the "Company") common stock.

F2 · derivative.exercise_date: One-third (1/3) of the RSUs subject to this grant under the Company's Amended and Restated 2015 Stock Incentive Plan, as amended (the "Plan"), will vest on each of the first three (3) anniversaries of the November 16, 2020 grant date (the "Grant Date"), subject to continued employment through each such vesting date.

F2 · derivative.expiration_date: One-third (1/3) of the RSUs subject to this grant under the Company's Amended and Restated 2015 Stock Incentive Plan, as amended (the "Plan"), will vest on each of the first three (3) anniversaries of the November 16, 2020 grant date (the "Grant Date"), subject to continued employment through each such vesting date.

SEC source: 0001209191-20-056737 · doc4.xml · derivative · entry 1

Alton Gregg H · CIK 0001334682 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 7,700

Underlying: Common Stock · 7,700 shares

Expires 2030-10-31

F1 · derivative.exercise_date: One hundred percent (100%) of the shares subject to this option grant under the Novavax, Inc. (the "Company") Amended and Restated 2015 Stock Incentive Plan, as amended, will vest one (1) year from the October 31, 2020 grant date subject to continued service on the Company's Board of Directors through the vesting date.

SEC source: 0001209191-20-052697 · doc4.xml · nonDerivative · entry 11

Erck Stanley C · CIK 0001342826 · Director · President and CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 20,494

F1 · kind: The transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person.

SEC source: 0001209191-20-052700 · doc4.xml · nonDerivative · entry 8

Trizzino John · CIK 0001468534 · EVP, CBO and CFO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 5,087

F1 · kind: The transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person.

F8 · price: The reported price is a weighted average price. These shares were sold in multiple transactions at prices ranging from $114.98 to $115.20, inclusive. The reporting person undertakes to provide to the Company, any security holder of the Company, or the staff of the SEC, upon request, full information regarding the number of shares purchased at each price within the range set forth in this footnote.